We are live on ! Find out more
CG

Carlyle Group Portfolio holdings

AUM $10.6B
1-Year Est. Return 11.25%
This Fund
S&P 500
This Quarter Est. Return
-11.02%
1 Year Est. Return
+11.25%
3 Year Est. Return
-0.47%
5 Year Est. Return
-4.92%
10 Year Est. Return
+7.54%
AUM
$1.59B
AUM Growth
-$493M
Cap. Flow
-$82.1M
Cap. Flow %
-5.17%
Top 10 Hldgs %
93.85%
Holding
33
New
8
Increased
4
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$54.9M
2
QTTB icon
Q32 Bio
QTTB
+$15.2M
3
DNUT icon
Krispy Kreme
DNUT
+$4.55M
4
JSPR icon
Jasper Therapeutics
JSPR
+$3.37M
5
SPWR icon
SunPower Inc
SPWR
+$2.42M

Top Sells

Rank Stock Value
1
GTM
ZoomInfo Technologies
GTM
+$146M
2
VERA icon
Vera Therapeutics
VERA
+$22.1M
3
GETY icon
Getty Images
GETY
+$841K
4
EFTR
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
+$12

Sector Composition

Rank Sector Weight
1 Healthcare 59.55%
2 Technology 28.63%
3 Consumer Staples 6.27%
4 Communication Services 2.41%
5 Real Estate 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.19B
$597M 37.66%
12,460,183
– –
GTM
2
ZoomInfo Technologies
GTM
$905M
$421M 26.52%
26,244,474
-9,000,000
-26% -$146M
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
$173M 10.91%
4,071,562
+1,213,758
+42% +$54.9M
VTRU
4
DELISTED
Vitru Limited Common Shares
VTRU
$94M 5.93%
6,246,471
– –
VRNA
5
DELISTED
Verona Pharma
VRNA
$39.4M 2.49%
2,457,500
– –
GETY icon
6
Getty Images
GETY
$216M
$38.2M 2.41%
9,212,799
-181,520
-2% -$841K
PHAT icon
7
Phathom Pharmaceuticals
PHAT
$873M
$37.1M 2.34%
3,496,808
– –
JSPR icon
8
Jasper Therapeutics
JSPR
$24.8M
$31.3M 1.97%
1,066,189
+190,000
+22% +$3.37M
HLVX
9
DELISTED
HilleVax
HLVX
$30.5M 1.92%
1,838,486
– –
GDS icon
10
GDS Holdings
GDS
$6.24B
$27.1M 1.71%
4,072,624
– –
SMHI icon
11
SEACOR Marine Holdings
SMHI
$214M
$18.3M 1.15%
1,314,164
– –
QTTB icon
12
Q32 Bio
QTTB
$255M
$18.1M 1.14%
+1,102,741
New +$15.2M
INVH icon
13
Invitation Homes
INVH
$17.9B
$17M 1.07%
477,500
– –
CUBE icon
14
CubeSmart
CUBE
$9.48B
$9.97M 0.63%
220,500
– –
ACET icon
15
Adicet Bio
ACET
$75.9M
$6.9M 0.44%
184,295
+52,083
+39% +$2.15M
DNUT icon
16
Krispy Kreme
DNUT
$569M
$5.19M 0.33%
+340,748
New +$4.55M
OKUR
17
OnKure Therapeutics
OKUR
$170M
$4.45M 0.28%
269,896
– –
EM
18
DELISTED
Smart Share Global Ltd
EM
$3.16M 0.2%
4,810,209
– –
EFTR
19
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$2.72M 0.17%
192,884
-1
-0% -$12
SPWR icon
20
SunPower Inc
SPWR
$102M
$2.72M 0.17%
4,936,483
+2,190,604
+80% +$2.42M
SPRB
21
Spruce Biosciences
SPRB
$120M
$2.28M 0.14%
38,620
– –
NABL icon
22
N-able
NABL
$899M
$1.23M 0.08%
+93,732
New +$1.24M
SWI
23
DELISTED
SolarWinds Corporation Common Stock
SWI
$1.18M 0.07%
+93,735
New +$1.14M
AVGO icon
24
Broadcom
AVGO
$1.76T
$1M 0.06%
+7,550
New +$935K
NU icon
25
Nu Holdings
NU
$65.6B
$863K 0.05%
+72,341
New +$739K
1
2

Similar funds

SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $10.8B AUM 21.99% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $10.9B AUM 18.64% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

Carlyle Group's Q1 2024 Portfolio in Review

As of Q1 2024, Carlyle Group held 33 positions worth $1.59B, down 24% from $2.08B the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Carlyle Group withdrew a net $82.1M in Q1 2024, closing 1 position and reducing 3 holdings. Its most notable exit was Vera Therapeutics, an estimated $22.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 57% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Carlyle Group opened a new position in Q32 Bio worth $18.1M.

  • Carlyle Group's largest Q1 2024 buy was Q32 Bio: 1,102,741 shares worth $18.1M.
  • Carlyle Group added most to Soleno Therapeutics in Q1 2024, an estimated $54.9M increase.
  • Carlyle Group's biggest Q1 2024 reduction was ZoomInfo Technologies, cutting an estimated $146M.
  • Carlyle Group fully exited Vera Therapeutics in Q1 2024, selling an estimated $22.1M.
  • Carlyle Group's ten largest holdings make up 94% of its $1.59B portfolio in Q1 2024.
  • Carlyle Group opened 8 new positions and closed 1 in Q1 2024.
  • Carlyle Group's portfolio value fell 24% quarter-over-quarter to $1.59B.

Based on Carlyle Group's 13F filing for Q1 2024, filed 3 May 2024.